He points out, "This approach of precision oncology uses the concept of theranostics--i.e., we see what we treat, and we treat what we see. 177Lu-PRLT patients were selected and followed-up with 68Ga-PSMA PET/CT, using the same ligand for molecular imaging and molecular radiotherapy."
Kulkarni adds, "These findings will help to determine the right place of 177Lu-PSMA radioligand therapy in the treatment of metastatic prostate cancer--for example before chemotherapy--and serve as a starting point for a prospective randomized controlled clinical trial."
Ad Statistics
Times Displayed: 19757
Times Visited: 367 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
ABOUT THE SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI's more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice.
Back to HCB News
